News
-
-
PRESS RELEASE
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Menarini Group and NewAmsterdam Pharma receive European Commission approval for Ubeslo and Evlarco, marking a milestone for cardiovascular disease treatment with LDL-C reduction therapies -
-
-
-
-
-
-
-
PRESS RELEASE
EQS-Adhoc: EPH Group AG: Purchase agreements signed for the acquisition of an approximately 26,363 m² property in Burgenland
EPH Group AG signs purchase agreements for 26,363 m² property in Burgenland to develop luxury resort. Total purchase price of EUR 263,630, subject to conditions precedent